SANTA CLARA, Calif., May 30, 2017 /PRNewswire/ -- The recent U.S. Food and Drug Administration (FDA) approval of
"Monoclonal antibody therapies are likely to emerge across AD in the near future, while for PD, gene therapeutic strategies could prove very effective," noted Frost & Sullivan TechVision Research Analyst Vandana Iyer. "Therapy developers are currently focusing on the identification of neurological biomarkers that facilitate early diagnosis of neurological conditions, as it will subsequently fuel enhanced therapeutic advancements."
Therapeutic Breakthroughs in Alzheimer's and Parkinson's Diseases is part of Frost & Sullivan's TechVision (Health & Wellness) Growth Partnership Service program. The research presents treatment overviews, emerging therapeutic platforms, intellectual property and funding analysis, and emerging innovation profiles across AD and PD. Further, it analyzes the impact of key technology drivers and restraints, and provides a summary of collaborative trends, regional adoption potential, innovative therapeutic platforms, and growth opportunities.
To know more about Frost & Sullivan's research and to sign up for our Growth Strategy Dialogue, a complimentary one-hour interactive session with Frost & Sullivan's thought leaders, please click here.
While there is considerable optimism among researchers, they have not been able to completely comprehend the pathology of neurodegenerative disorders or distinguish between healthy aging and neurodegeneration at the initial stages of the diseases. The risk of therapeutic failures is also high during early clinical studies of neurological disorders.
Strong therapeutic platforms for AD and PD will eventually allow drug developers to create therapies for all neurodegenerative diseases. The leading regions for AD and PD research are:
Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence, and provides a variety of technology-based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
Therapeutic Breakthroughs in Alzheimer's and Parkinson's DiseasesD7B4
Contact:Mariana FernandezCorporate Communications North AmericaP: +54 11 4778 3540F: +54 11 4777 0071E: Mariana.Fernandez@frost.com
Twitter: @TechVision_FSLinkedin: www.frost.com/techvisionlinkedin
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/targeted-immunotherapies-and-gene-therapies-to-unlock-new-growth-opportunities-in-alzheimers-and-parkinsons-clinical-management-300465325.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...
Palliative care is a specialized multifaceted care for patients with chronic or terminal illness to ...View All